CN114340618A - 减轻与翼状胬肉相关的对眼外观的担忧的方法 - Google Patents

减轻与翼状胬肉相关的对眼外观的担忧的方法 Download PDF

Info

Publication number
CN114340618A
CN114340618A CN202080061833.2A CN202080061833A CN114340618A CN 114340618 A CN114340618 A CN 114340618A CN 202080061833 A CN202080061833 A CN 202080061833A CN 114340618 A CN114340618 A CN 114340618A
Authority
CN
China
Prior art keywords
patient
symptoms
reducing
signs
reported
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080061833.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.倪
S.惠特卡普
R.杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poyun Biomedical Technology Guangzhou Co ltd
Original Assignee
Cloudbreak Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cloudbreak Therapeutics LLC filed Critical Cloudbreak Therapeutics LLC
Publication of CN114340618A publication Critical patent/CN114340618A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eye Examination Apparatus (AREA)
CN202080061833.2A 2019-09-10 2020-09-10 减轻与翼状胬肉相关的对眼外观的担忧的方法 Pending CN114340618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898401P 2019-09-10 2019-09-10
US62/898,401 2019-09-10
PCT/US2020/050150 WO2021050692A2 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Publications (1)

Publication Number Publication Date
CN114340618A true CN114340618A (zh) 2022-04-12

Family

ID=74870040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080061833.2A Pending CN114340618A (zh) 2019-09-10 2020-09-10 减轻与翼状胬肉相关的对眼外观的担忧的方法

Country Status (10)

Country Link
US (1) US20220331310A1 (enExample)
EP (1) EP4027997A4 (enExample)
JP (1) JP2022547401A (enExample)
KR (1) KR20220061147A (enExample)
CN (1) CN114340618A (enExample)
AU (2) AU2020346812A1 (enExample)
BR (1) BR112021026662A2 (enExample)
CA (1) CA3146811A1 (enExample)
MX (1) MX2022000468A (enExample)
WO (1) WO2021050692A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260025887A (ko) 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
WO2013188268A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
WO2017210132A1 (en) * 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US20170368061A1 (en) * 2015-06-22 2017-12-28 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
CN110072849A (zh) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180252A1 (es) * 2015-06-09 2018-02-02 Bayer Pharma AG Moduladores alostericos positivos del receptor muscarinico m2
CN108602879A (zh) * 2016-02-04 2018-09-28 倪劲松 用于治疗疾病的抗体-药物协同作用技术
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
AU2019272871B2 (en) * 2018-05-25 2025-02-27 Ads Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
WO2013188268A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US20170172915A1 (en) * 2015-06-06 2017-06-22 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
CN108135737A (zh) * 2015-06-06 2018-06-08 克劳德布雷克医疗有限责任公司 用于治疗翼状胬肉的组合物和方法
US20170368061A1 (en) * 2015-06-22 2017-12-28 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
CN107708664A (zh) * 2015-06-22 2018-02-16 新源生物科技股份有限公司 酪胺酸激酶抑制剂的眼用调配物、其使用方法、及其制备方法
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
WO2017210132A1 (en) * 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
CN110072849A (zh) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
徐硕;等: "角膜新生血管药物治疗的最新进展", 眼科新进展, vol. 35, no. 10, 31 October 2015 (2015-10-31), pages 989 - 993 *
王晓春;等: "翼状胬肉切除联合自体结膜移植术疗效观察", 中国眼耳鼻喉科杂志, vol. 12, no. 05, 25 September 2012 (2012-09-25), pages 315 - 316 *

Also Published As

Publication number Publication date
AU2020346812A1 (en) 2022-01-27
AU2026202351A1 (en) 2026-04-16
EP4027997A2 (en) 2022-07-20
BR112021026662A2 (pt) 2022-04-12
WO2021050692A3 (en) 2021-05-14
EP4027997A4 (en) 2023-10-11
JP2022547401A (ja) 2022-11-14
US20220331310A1 (en) 2022-10-20
KR20220061147A (ko) 2022-05-12
WO2021050692A2 (en) 2021-03-18
MX2022000468A (es) 2022-02-03
CA3146811A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US11648261B2 (en) Method of treating, reducing, or alleviating a medical condition in a patient
TWI714596B (zh) 用於治療翼狀胬肉之組合物及方法
JP7278257B2 (ja) 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
US20200360386A1 (en) Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions
AU2026202351A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
US20240398736A1 (en) Eyedrops for Treating Scleral Thinning and Screening Method for Therapeutic Agent of Scleral Thinning
HK40068230A (en) Methods for alleviating pterygium-associated worry about eye appearance
Varshney et al. Ropivacaine versus bupivacaine-lignocaine mixture in peribulbar block-A comparative study
Humayun et al. Mechanical epithelial debridement< em> versus transepithelial phototherapeutic keratectomy followed by accelerated corneal collagen crosslinking for progressive keratoconus
Juan et al. Pterygium Recurrence Prevention Utilizing Mitomycin C Washing, Case Series
Bansal et al. A comparative analysis of 0.3% Nepafenac alone vs 0.1% Nepafenac vs 0.5% Loteprednol to control post operative inflammation in patients who underwent uneventful phacoemulsification cataract surgery
HK40061312B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40061312A (en) Compounds for treatment of eye diseases associated with excessive vascularisation
HK40101374A (en) Compositions and methods for treating pterygium
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤
JP5978471B2 (ja) 耳鳴患者の治療用の薬剤
Kronemyer Surgical treatments range from cross-linking to keratoplasty when keratoconus progresses.
Johnson Surgery and complications-refractive surgery. Diffuse lamellar keratitis
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20220506

Address after: Room 327, building G1, No. 31 Kefeng Road, Huangpu District, Guangzhou, Guangdong

Applicant after: Poyun biomedical technology (Guangzhou) Co.,Ltd.

Address before: California, USA

Applicant before: CLOUDBREAK THERAPEUTICS LLC

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068230

Country of ref document: HK

CB02 Change of applicant information

Country or region after: China

Address after: 510663 room 327, building G1, No. 31 Kefeng Road, Huangpu District, Guangzhou, Guangdong

Applicant after: Pokvision Cloud Biomedical Technology (Guangzhou) Co.,Ltd.

Address before: 510663 room 327, building G1, No. 31 Kefeng Road, Huangpu District, Guangzhou, Guangdong

Applicant before: Poyun biomedical technology (Guangzhou) Co.,Ltd.

Country or region before: China

CB02 Change of applicant information